ACRIVASTINE VERSUS TERFENADINE IN THE TREATMENT OF SYMPTOMATIC DERMOGRAPHISM - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
- 1 January 1989
- journal article
- research article
- Vol. 17, B9-B13
Abstract
Twelve patients with symptomatic dermographism were entered into a double-blind, crossover study. Patients received 8 mg acrivastine three times daily, 60 mg terfenadine three times daily or placebo, according to a fully randomized balanced treatment plan. Subjective clinical assessments were performed and the response to experimentally induced dermographism was assessed. Both active treatments were well tolerated and were shown to be significantly more effective than placebo in the treatment of symptomatic dermographism and in reducing the signs and symptoms of wealing induced by a dermographometer.This publication has 5 references indexed in Scilit:
- ACRIVASTINE - AN EVALUATION OF INITIAL AND PEAK ACTIVITY IN HUMAN-SKIN1989
- Comparison of the New Antihistamine Acrivastine (BW 825C) versus Cyproheptadine in the Treatment of Idiopathic Cold UrticariaDermatology, 1988
- The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effectsClinical Pharmacology & Therapeutics, 1985
- The effect of terfenadine on dermographic wealingBritish Journal of Dermatology, 1984
- An Assessment of the Novel Antihistamine BW 825C in the Treatment of Chronic Idiopathic UrticariaDermatology, 1984